Cargando…
Risk of tuberculosis reactivation with rituximab therapy
BACKGROUND: Tuberculosis (TB) is one of the world’s deadliest diseases, and one-third of the world’s population is infected with it. The link between antitumor necrosis factor therapy and reactivation of latent TB is well recognized. However, only limited studies have evaluated the risk of TB with r...
Autores principales: | Alkadi, Amjad, Alduaiji, Najla, Alrehaily, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Qassim Uninversity
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426414/ https://www.ncbi.nlm.nih.gov/pubmed/28539862 |
Ejemplares similares
-
Rituximab Administration and Reactivation of HBV
por: Tsutsumi, Yutaka, et al.
Publicado: (2010) -
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016) -
Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015) -
Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
por: Yoo, Dae San, et al.
Publicado: (2020) -
Rituximab-induced pneumonitis mimicking miliary tuberculosis
por: Yao, Chih-Wei, et al.
Publicado: (2013)